Home / Companies / Ardez Spol.
Company family
Ardez Spol.: medicine shortages
As of 2 Nov 2026, 5 Ardez Spol. products have a reported shortage across 1 countries, covering 4 medicines.
Products short5rank #318 of 464
Medicines4active ingredients
Countries1/16
New in 90 days1+1 vs market pace
Typical duration3.7 yearsmedian so far
Manufacturing60%demand-driven 0%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
Latest changes
All changesNo changes recorded yet. Changes are tracked from our daily snapshots.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
Download CSV| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Pregabalin | 2 | 1 Mar 2023 | Commercial decision or withdrawal | 11/16 | |
| Bicalutamide | 1 | 1 Dec 2026 | Manufacturing problem | 6/16 | |
| Olanzapine | 1 | 2 Sep 2026 | Manufacturing problem | 13/16 | |
| Solifenacin | 1 | 1 Dec 2026 | Manufacturing problem | 6/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.